Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors

The 20 members of the Rho GTPase family are key regulators of a wide-variety of biological activities. In response to activation, they signal via downstream effector proteins to induce dynamic alterations in the organization of the actomyosin cytoskeleton. In this review, post-translational modifica...

Descripción completa

Detalles Bibliográficos
Autor principal: Olson, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927519/
https://www.ncbi.nlm.nih.gov/pubmed/27548350
http://dx.doi.org/10.1080/21541248.2016.1218407
_version_ 1783319101997842432
author Olson, Michael F.
author_facet Olson, Michael F.
author_sort Olson, Michael F.
collection PubMed
description The 20 members of the Rho GTPase family are key regulators of a wide-variety of biological activities. In response to activation, they signal via downstream effector proteins to induce dynamic alterations in the organization of the actomyosin cytoskeleton. In this review, post-translational modifications, mechanisms of dysregulation identified in human pathological conditions, and the ways that Rho GTPases might be targeted for chemotherapy will be discussed.
format Online
Article
Text
id pubmed-5927519
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-59275192018-05-02 Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors Olson, Michael F. Small GTPases Reviews The 20 members of the Rho GTPase family are key regulators of a wide-variety of biological activities. In response to activation, they signal via downstream effector proteins to induce dynamic alterations in the organization of the actomyosin cytoskeleton. In this review, post-translational modifications, mechanisms of dysregulation identified in human pathological conditions, and the ways that Rho GTPases might be targeted for chemotherapy will be discussed. Taylor & Francis 2016-08-22 /pmc/articles/PMC5927519/ /pubmed/27548350 http://dx.doi.org/10.1080/21541248.2016.1218407 Text en © 2016 The Author. Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Reviews
Olson, Michael F.
Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title_full Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title_fullStr Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title_full_unstemmed Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title_short Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
title_sort rho gtpases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927519/
https://www.ncbi.nlm.nih.gov/pubmed/27548350
http://dx.doi.org/10.1080/21541248.2016.1218407
work_keys_str_mv AT olsonmichaelf rhogtpasestheirposttranslationalmodificationsdiseaseassociatedmutationsandpharmacologicalinhibitors

Ejemplares similares